Cibus (NASDAQ:CBUS) Stock Rating Lowered by Wall Street Zen

Cibus (NASDAQ:CBUS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research report on Friday, September 25th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cibus presently has an average rating of “Hold” and an average price target of $9.00.

Cibus Price Performance

CBUS opened at $1.32 on Friday. Cibus has a 1 year low of $1.09 and a 1 year high of $4.19. The company has a market capitalization of $100.89 million, a price-to-earnings ratio of -0.80 and a beta of 1.57. The firm’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $1.57.

Cibus (NASDAQ:CBUS) last announced its earnings results on Thursday, August 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.10). Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%. The firm had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.70 million. As a group, equities analysts anticipate that Cibus will post -1.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CBUS. Nautilus Advisors LLC bought a new position in Cibus in the 3rd quarter valued at $35,000. Rockland Trust Co. purchased a new stake in shares of Cibus during the 2nd quarter valued at $41,000. Bank of America Corp DE increased its position in shares of Cibus by 324.2% during the 1st quarter. Bank of America Corp DE now owns 74,358 shares of the company’s stock valued at $147,000 after purchasing an additional 56,830 shares during the last quarter. Weiss Asset Management LP bought a new stake in shares of Cibus during the 1st quarter worth $1,758,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Cibus during the 1st quarter worth $66,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc is an agricultural biotechnology company focused on developing and commercializing gene-edited traits for major crops. Its technology is designed to make precise changes to a plant’s existing genes without introducing foreign DNA, supporting the development of improved crop varieties through a process intended to resemble conventional breeding.

The company’s product development programs target traits such as herbicide tolerance, disease resistance, improved yield, and other characteristics intended to benefit farmers, seed companies, and the broader food and agriculture supply chain.